🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On this National Cancer Survivors Month, we at ESSA celebrate the strength, resilience, and courage of all cancer survivors. Your journeys fuel our commitment to developing innovative treatments. #NationalCancerSurvivorsMonth

Happy Father’s Day!

Today, we recognize #Juneteenth, a day celebrating the end of slavery in the United States.

Happy Canada Day to everyone who celebrates the anniversary of Canadian Confederation!

We want to wish everyone a happy and safe Fourth of July! #IndpendenceDay

Tomorrow, ESSA CEO & President David R. Parkinson will present at the Jones Healthcare Seaside Summit. A link to the live webcast is available on the Events and Presentations section of the ESSA website: bit.ly/3S2NEIk

ESSA hopes that men all over the world remember that regular screening is so important, especially because early detection often results in an improved outcome. Please include regular prostate screenings in your routine.

ESSA Pharma reports financial results for the quarter ended June 30, 2024, and provides a business update. Read the release here: bit.ly/4cgoRYx

ESSA Pharma hopes that men everywhere recognize the importance of regular screenings and detection for prostate cancer. Learn more about screening for prostate cancer here: bit.ly/3zOdjOy

Did you know that prostate cancer is the second most frequently diagnosed cancer among men with 1 in 8 men likely to be diagnosed in their lifetime? That’s why we’re working diligently to find a cure for the disease. Learn more about our science here: bit.ly/4d7K4Vk

Wishing everyone a happy and safe #LaborDay!

Next week, at @ESMO, we will present a poster with updated data from our phase 1/2 clinical trial of masofaniten + enzalutamide for patients with castration-resistant #prostatecancer. #ESMO2024

September is Prostate Cancer Awareness Month! At ESSA, we are developing the next generation of treatments for prostate cancer. For more information on prostate cancer and how to spread awareness, visit: pcf.org

Today, we will present updated data from our phase 1/2 clinical trial of masofaniten in combination with enzalutamide (Enz) compared to Enz alone in metastatic castration-resistant #prostatecancer subjects at the #ESMO 2024 at 12:00pm CET. bit.ly/3zgtd4z

Tomorrow, ESSA’s management team will present at the Cantor Global Healthcare Conference. A link to the live webcast is available on the Events and Presentations Section of the ESSA website: bit.ly/3Zw3Vdh

As Prostate Cancer Awareness Month draws to a close, ESSA Pharma hopes that men recognize the importance of regular screenings and detection for prostate cancer. Learn more about screening here: bit.ly/3zOdjOy

Recently, we announced updated Phase 1/2 masofaniten clinical data at #ESMO2024, showing that the combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients in mCRPC. Learn more here: bit.ly/4d8fHxP

Our recently updated Phase 1/2 masofaniten clinical data showed rapid, deep and durable reductions in PSA in patients in mCRPC, regardless of previous chemotherapy status. Learn more here: bit.ly/4d8fHxP

Did you know that about 1/3 of patients with early-stage prostate cancer will experience rising levels of prostate specific antigen? This is a sign that the disease is progressing. Learn more about early detection and screening for prostate cancer here: bit.ly/4de8Pih

Our lead drug candidate masofaniten is a first-in-class N terminal domain androgen receptor (AR) inhibitor in development for the treatment of AR-driven prostate cancer. Learn more about masofaniten here: bit.ly/4d7K4Vk